In the last trading session, 1.28 million shares of the Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) were traded, and its beta was 1.06. Most recently the company’s share price was $0.93, and it changed around $0.06 or 7.19% from the last close, which brings the market valuation of the company to $79.99M. PIRS currently trades at a discount to its 52-week high of $2.12, offering almost -127.96% off that amount. The share price’s 52-week low was $0.72, which indicates that the current value has risen by an impressive 22.58% since then. We note from Pieris Pharmaceuticals Inc.’s average daily trading volume that its 10-day average is 1.97 million shares, with the 3-month average coming to 627.49K.
Pieris Pharmaceuticals Inc. stock received a consensus recommendation rating of a Buy, based on a mean score of 1.30. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended PIRS as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Pieris Pharmaceuticals Inc. is expected to report earnings per share of -$0.17 for the current quarter.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) trade information
Instantly PIRS has showed a green trend with a performance of 7.19% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.9699 on Tuesday, 05/23/23 increased the stock’s daily price by 4.11%. The company’s shares are currently down -10.53% year-to-date, but still up 16.46% over the last five days. On the other hand, Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) is 6.95% up in the 30-day period. We can see from the shorts that 1.86 million shares have been sold at a short interest cover period of 5.08 day(s).
The consensus price target as assigned by Wall Street analysts is $7.00, which translates to bulls needing to increase their stock price by 86.71% from its current value. Analyst projections state that PIRS is forecast to be at a low of $7.00 and a high of $7.00. In order for the stock price to hit the forecast high, the stock would need to plunge -652.69% from its current level, while the stock would need to crash -652.69% from its current level to reach the projected low.
Pieris Pharmaceuticals Inc. (PIRS) estimates and forecasts
Pieris Pharmaceuticals Inc. share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -2.34 percent over the past six months and at a -57.78% annual growth rate that is well below the industry average of 11.20%. Moreover, analysts have decided to roll up on their fiscal year 2023 revenue estimates. The rating firms predict that it will loss -21.40% in revenue this quarter, and will report a decrease of -46.20% in the next quarter. The year-over-year growth rate is expected to be -53.70%, down from the previous year.
Consensus estimates provided by 2 financial analysts predict the company will bring in an average of $3.76 million in revenue for the current quarter. 2 analysts expect Pieris Pharmaceuticals Inc. to make $2.76 million in revenue for the quarter ending Sep 2023. The company’s sales for the same quarters a year ago were $3.7 million and $5.37 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 1.70%. Forecasts for the next quarter put sales growth at -48.60%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -2.20%.
Pieris Pharmaceuticals Inc.’s next quarterly earnings report is expected to be released around August 02 and August 07.
Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.85% of Pieris Pharmaceuticals Inc. shares, and 59.36% of them are in the hands of institutional investors. The stock currently has a share float of 65.84%. Pieris Pharmaceuticals Inc. stock is held by 74 institutions, with Lynx1 Capital Management Lp being the largest institutional investor. By Mar 30, 2023, it held 8.62% of the shares, which is about 7.07 million shares worth $6.9 million.
BVF Inc., with 6.19% or 5.08 million shares worth $4.96 million as of Mar 30, 2023, holds the second largest percentage of outstanding shares.
Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund were the top two Mutual Funds as of Dec 30, 2022. The former held 0.87 million shares worth $0.91 million, making up 1.17% of all outstanding shares. On the other hand, Fidelity Extended Market Index Fund held roughly 0.36 million shares worth around $0.54 million, which represents about 0.48% of the total shares outstanding.